Compare stocks

ONCY vs XRTX

Oncolytics Biotech, Inc. Common Shares and XORTX Therapeutics Inc. Common Stock

Compare the businesses

Oncolytics Biotech, Inc. Common Shares

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Open ONCY dashboard ↗

XORTX Therapeutics Inc. Common Stock

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.

Open XRTX dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗